Immobilized single chain antibodies for affinity purification of recombinant human IFN-α2b

Pavlo Gilchuk(AstraZeneca (Japan)), O. Ya. Yakovenko(Taras Shevchenko National University of Kyiv), O. V. Okunev(National Academy of Sciences of Ukraine), Д. М. Іродов(National Academy of Sciences of Ukraine), M. V. Pavlova(Taras Shevchenko National University of Kyiv)
Biopolymers and Cell
March 20, 2006
10.7124/bc.00072b
Cited by 3

Related Papers

Potently neutralizing and protective human antibodies against SARS-CoV-2
|Nature|2020|1.2k
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
|Cell Host & Microbe|2020|1.2k
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
|Nature Medicine|2021|1k
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
|Nature Medicine|2020|543
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
|Cell|2021|409